智通财经APP获悉，中国生物制药(01177)绩后高开逾6%，截至发稿，涨6.05%，报5.08港元，成交额1573.45万港元。
消息面上，8月19日，中国生物制药正式公布2026年中期业绩，数据呈现出罕见的高增长态势，不仅营收再创历史新高达到194.4亿元，同比增长10.6%，核心业务经调整归母净利润也实现33.4亿元的稳健增长，同比增速达92.3%。2026年上半年，随着罗伐昔替尼、培来加南、纳地美定等创新产品获批，以及安罗替尼、库莫西利、宗艾替尼等核心产品适应症进一步拓展，公司创新业务正在进入集中兑现期。
值得一提的是，上半年，中生以源头创新持续赢得全球顶级药企的背书。截至目前，集团累计完成4项重磅对外授权，交易总规模逾70亿美元，首付款合计超10亿美元，意味着中生的研发实力、生产质控已获得国际顶尖MNC的全方位认证，BD出海正走向“常态化输出”。同时，在AI与国际化两大战略旗帜下，中生在肿瘤、肝病/心血管代谢、呼吸/自免、外科/镇痛四大核心治疗领域的管线厚度正在转化为密集的商业化成果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.